NEWS FREESTYLE LIBRE DELETION FROM DRUG TARIFF
Abbott has confirmed that the original FreeStyle Libre sensor will be discontinued in the UK by 31 December 2022. This product is due to be deleted from Part 9 of the January 2023 Drug Tariff.
Contractors should note that as this line will be deleted from the January Drug Tariff, any prescriptions submitted for payment after
submission of your December bundle will not be passed for payment.
Contractors are advised to: • Only order stock to fulfill prescriptions. Do not hold additional stock above patient need
• Inform patients currently using FreeStyle Libre sensors of the discontinuation and direct them to contact their GP
NEW TREATMENT FOR NEURODEGENERATIVE DISEASE
• In December ensure that any outstanding prescriptions are submitted with your December bundle
Please note this discontinuation does not impact FreeStyle Libre 2 sensor.
If you have any questions about this, or other unavailable products, please contact us on 0131 466 3540 or at
pharmacy.services@
cps.scot.
MONKLANDS REPLACEMENT PROJECT
The Monklands Replacement Project to develop a new hospital at Wester Moffat, Airdrie, has reached another milestone.
NHS Lanarkshire Board met on Wednesday 30 November 2022 to consider a draft outline business case (OBC) for the new hospital. The Board agreed to submit the OBC to the Scottish Government for their consideration and approval as the next stage in the formal approval process. In approving the business case, the Board acknowledged the current uncertainty surrounding the overall UK and Scottish fiscal position and the potential impact on the project.
Scientists have found a new drug treatment that can slow the progression of neurodegenerative disease in mice. The breakthrough research may offer fresh hope in tackling currently untreatable conditions such as Alzheimer’s disease.
The study - led by researchers at the University of Glasgow’s new Advanced Research Centre (ARC) and published today in Science Signaling – found that by using a novel drug, which selectively activates a brain protein called the M1-receptor, the lifespan of mice suffering from neurodegeneration could be extended. The M1- receptor is a key brain protein, involved in memory and learning in people, and is an important potential target for neurodegenerative disease treatment.
Currently, Alzheimer’s disease is the most common form of neurodegenerative disease, affecting more than 850,000 people in the UK and over 55 million worldwide. The study
22
scottishpharmacist.com
demonstrates how many of the features of human Alzheimer’s disease, including memory loss and inflammation of the brain, could be treated in mice when they were given the new drug, known as a positive allosteric modulator (M1-PAM). The breakthrough described in this study indicates that, beyond treating symptoms, M1-PAMs may also be able to slow the overall progression of the disease.
The drug used in the study is the result of over a decade of research from the teams at Vanderbilt University in Nashville, Tennessee and the University of Glasgow. The Vanderbilt University team are currently testing an M1-PAM in humans as a treatment for memory loss in Alzheimer’s disease (AD) patients. The remarkable finding, which was published recently, points to the prospect that the M1-PAM currently being tested on AD patients for memory loss might also actually slow the progression of Alzheimer’s disease.
Colin Lauder, NHS Lanarkshire’s Director of Planning, Performance and Property said: ‘This is an important milestone and we would like to thank all of the many staff and other stakeholders for the enormous amount of work they have done to bring the project to this stage. We recognise this is a challenging time to bring forward such a major capital development given the wider financial pressures. However, there is a strong business case to do so. In order to give the project the best chance of moving through the funding approval process the OBC includes a revised timescale for the ground works at Wester Moffat. It had originally been hoped to begin ground works at Wester Moffat next year by seeking early release of funding prior to final approval of the full business case. We have now scheduled the ground works for later in the project timeline at a point when there is expected to be greater clarity on the overall financial position of NHS Scotland.’
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
